AGE - AgeX Therapeutics Inc
Previous close
11.1
0 0%
Share volume: 21,904
Last Updated: Tue 26 Mar 2024 05:00:00 AM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$11.10
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-13 | 2022-08-12 | 2022-11-10 | 2023-03-31 | 2023-05-12 | 2023-08-14 | 2023-11-14 | |
| Assets | ||||||||
| Total Assets | 2.716 M | 2.579 M | 2.008 M | 3.241 M | 12.531 M | 12.277 M | 12.210 M | |
| Current Assets | 1.829 M | 1.725 M | 1.187 M | 2.453 M | 1.747 M | 1.350 M | 1.141 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.381 M | 1.011 M | 720.000 K | 1.804 M | 1.461 M | 1.083 M | 673.000 K | |
| Short Term Investments | 1.381 M | 1.011 M | 720.000 K | 1.804 M | 1.461 M | 1.083 M | 673.000 K | |
| Total Receivables | 0.000 | 12.000 K | 1.000 K | 4.000 K | 6.000 K | 6.000 K | 71.000 K | |
| Current Cash | 448.000 K | 702.000 K | 466.000 K | 645.000 K | 280.000 K | 261.000 K | 397.000 K | |
| Total Non-current Assets | 887.000 K | 854.000 K | 821.000 K | 788.000 K | 10.784 M | 10.927 M | 11.069 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 50.000 K | 50.000 K | 0.000 | 0.000 | 10.029 M | 10.204 M | 10.379 M | |
| Intangible Assets | 837.000 K | 804.000 K | 771.000 K | 738.000 K | 705.000 K | 673.000 K | 640.000 K | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 2.716 M | 2.579 M | 2.008 M | 3.241 M | 12.531 M | 12.277 M | 12.210 M | |
| Total liabilities | 14.263 M | 15.797 M | 17.112 M | 20.453 M | 32.425 M | 34.452 M | 3.788 M | |
| Total current liabilities | 10.099 M | 9.085 M | 8.809 M | 10.078 M | 22.525 M | 24.505 M | 3.204 M | |
| Accounts Payable | 69.000 K | 69.000 K | 59.000 K | 141.000 K | 144.000 K | 230.000 K | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 6.657 M | 6.968 M | 7.298 M | 7.646 M | 20.042 M | 22.943 M | 1.526 M | |
| Long term debt | 4.208 M | 6.756 M | 8.348 M | 10.478 M | 10.011 M | 10.068 M | 693.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | -44.000 K | -44.000 K | -45.000 K | -103.000 K | -111.000 K | -121.000 K | -109.000 K | |
| Total Shareholder equity | -11.547 M | -13.218 M | -15.104 M | -17.212 M | -19.894 M | -22.175 M | 8.422 M | |
| Common stock | 37.942 M | 37.943 M | 37.946 M | 37.949 M | 37.950 M | 37.951 M | 37.951 M | |
| Retained earnings | -108.454 M | -111.072 M | -113.507 M | -116.210 M | -119.487 M | -122.156 M | -127.557 M |